Clinical trial
A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL
NCT01031628 is registered in ClinicalTrials.gov with Sarcoma Alliance for Research through Collaboration as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Phase 3 Study of Dose Escalation Versus No Dose Escalation of Imatinib In Metastatic GIST Patients With Imatinib Trough Levels Less Than 1100 Nanograms/mL
- Lead sponsor
- Sarcoma Alliance for Research through Collaboration
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- January 31, 2010
- Completion date
- June 30, 2011
- Enrollment
- 5 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.